Skip to content

Berlin-Brandenburg Pregnancy Cohort

Characterization of Immune Cell-trophoblast-interaction in Pregnancy Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03313024
Acronym
BBPC
Enrollment
1580
Registered
2017-10-18
Start date
2017-09-26
Completion date
2027-10-31
Last updated
2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus in Pregnancy, Preeclampsia, Pregnancy Complications

Brief summary

This study will investigate the interplay of different immune cells and placental cells as well as their potential for the development of pregnancy complications. In particular, the translation of the uteroplacental syndrome into a maternal syndrome, considered in the multifactorial pregnancy disorder preeclampsia, will be investigated. Immune cell subtypes are causally involved in the formation and translation of preeclampsia by inducing an endothelial dysfunction which leads to cardiovascular damage.

Interventions

None listed

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy pregnant women after giving informed consent * pregnant with diagnosis of preeclampsia, gestational hypertension or gestational diabetes

Exclusion criteria

* infections * alcohol and drug abuse * manifest and chronic diseases

Design outcomes

Primary

MeasureTime frame
T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometryat the time of preeclampsia diagnosis compared to controls at the same time point in pregnancy

Countries

Germany

Contacts

Primary ContactFlorian Herse, PhD
florian.herse@charite.de+49 30 450 540 434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026